Immix Biopharma (IMMX) Retained Earnings (2020 - 2026)

Immix Biopharma has reported Retained Earnings for 7 years, with the latest figure at -$114.5 million in Q1 2026.

• Quarterly Retained Earnings fell 740900.43% year-over-year to -$114.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.5 million (down 740900.43% YoY) and the FY2025 annual result came in at -$104.5 million, down 9892256.44% from the prior year.
• Retained Earnings eased to -$114.5 million in Q1 2026 per IMMX's latest filing, from -$104.5 million in the prior quarter.
• Over five years, Retained Earnings peaked at $90.9 million in Q2 2025 and troughed at -$114.5 million in Q1 2026.
• A 5-year average of -$5.6 million and a median of $82547.0 in 2023 frame the typical range for Retained Earnings.
• The widest YoY moves for Retained Earnings: up 77589.43% in 2025, down 9892256.44% in 2025.
• Over 5 years, Retained Earnings stood at -$38.0 million in 2022, then surged by 100.35% to $134666.0 in 2023, then slumped by 100.78% to -$1056.0 in 2024, then sank by 9892256.44% to -$104.5 million in 2025, then dropped by 9.66% to -$114.5 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$114.5 million, -$104.5 million, and -$93.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.